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INTRODUCTION 
Four classes of immunosuppressive drugs have been used to treat human 
autoimmune diseases: corticosteroids, alkylating agents (cyclophosphamide 
and chlorambucil), antimetabolites (azathioprine and methotrexate) and more 
recently, cydosporine A (CsA). Before the advent of CsA, which was approved 
by the US Food and Drug Administration (FDA) for the therapy of organ 
allograft rejection in 1983, the successful use of immunosuppressive drugs in 
autoimmune disease was restricted to a handful of disorders. These included 
systemic lupus erythematosus (SLE), rheumatoid arthritis, myasthenia gravis 
and nephrotic syndrome. The use of CsA, which selectively inhibits T -lym-
phocyte activation and cytokine production has resulted in a higher rate of 
improvement than previously observed in those autoimmune diseases with a 
presumed T cell pathogenesis. These diverse disorders include psoriasis, atopic 
dermatitis, uveitis, insulin-dependent (type I) diabetes mellitus. primary bil-
iary cirrhosis, aplastic anemia and lichen planus. In contrast. autoimmune dis-
eases that are believed to be mediated primarily by autoantibodies. such as the 
autoimmune cytopenias. myasthenia gravis. SLE, Graves' disease and the 
glomerulonephritides are relatively resistant to CsA. In addition to the im-
proved rate of response seen with CsA, opportunistic infections (a potentially 
serious complication of cytotoxic drug administration) are very rare in CsA-treated 
autoimmune disease patients. 
Despite the successes achieved with CsA. several important problems still 
exist with respect to the immunosuppressive therapy of autoimmune diseases. 
These include: (1) an insufficient response rate; (2) disease recurrence follow-
ing drug withdrawal (failure to induce tolerance); and (3) the associated risks 
of drug toxicity or excessive immunosuppression (including infectious com-
plications and malignancy). With respect to CsA. the most common side ef-
fects are nephrotoxicity (including arterial hypertension), cosmetic deformity 
with hirsutism and coarsening of the facies. hypercholesterolemia and an in-
creased disposition to diabetes mellitus. Resolution of these difficulties has 
become the incentive for discovery of new immunosuppressive agents that act 
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specifically on components of the immune system that 
are involved in disease pathogenesis and not on "thera-
peutically irrelevant" cells. A wide range of new can-
didate drugs that act at different stages of lympho-
cyte activation/ proliferation are currently under 
development (Table 10.3.1). Of these new agents, 
tacrolimus (formerly known as FKS06), that has a 
similar mode of action to CsA but is considerably 
more potent, has recently been approved (April 1994) 
by the FDA for the therapy of liver allograft rejec-
tion. Its efficacy in the prevention of allograft rejec-
tion is well documented; more germane to the au-
toimmune disease field however, is the ability of 
tacrolimus to reverse established rejection-an immu-
nopathologic process that shares cellular and molecular 
mechanisms with many autoimmune disorders. Pre-
clinical evaluation of the efficacy and safety of 
tacrolimus in experimental autoimmune disorders is 
an important process in the evaluation of its thera-
peutic potential. This chapter briefly reviews the mode 
of action of tacrolimus and its influence on experi-
mental autoimmunity. 
MODE OF ACTION 
OF TACROLIMUS 
The powerful anti-lymphocytic and immunosup-
pressive properties of tacrolimus (C44H69N012eH20; 
mw 822), a fungally-derived macrocyclic lactone, were 
first documented in 1987.1.2 Although totally distinct 
in structure from the fungal product and cyclic pep-
tide CsA, tacrolimus shares many of the properties 
of the latter immunosuppressant. Both agents exhibit 
very similar molecular actions which result in the 
selective inhibition of C04> T helper (TH) lympho-
cyte activation, cytokine-gene expression and conse-
quently, lymphocyte proliferation. Like CsA, tacrolimus 
inhibits T cell activation mediated via the T cell re-
ceptor (TCR)-C03 complex and the cell surface 
molecule C02. It is very effective in suppressing lym-
phocyte proliferation in vitro at concentrations 100-
fold lower than effective concentrations of CSA.2.4 
T acrolimus inhibits the generation of cytotoxic T cells 
in human mixed lymphocyte reactions but does not 
affect antigen recognition by cytotoxic T cells or the 
mechanism by which target cells are destroyed. 5 
Tacrolimus does not appear to inhibit antigen pro-
cessing or presentation by human monocytes at drug 
concentrations which strongly suppress T cell prolif-
eration.6 Tacrolimus does not affect Cal. mobiliza-
tion, phosphatidylinositol turnover, or protein kinase 
C (PKC) activities. It does, however, strongly and 
specifically inhibit expression of early T cell activa-
tion genes encoding interleukin-2 (IL-2) (the main 
growth factor for T cells) IL-3, IL-4, IFN-y, granu-
locyte macrophage-colony stimulating factor (GM-CSF) 
and c-myc:' On the other hand, recent studies have 
shown that tacrolimus may spare IL-10 (cytokine syn-
thesis inhibitory factor) gene transcription by cloned 
murine T helper-2 (TH 2) cells in viero, whilst sup-
pressing concomitant IL-4 mRNA production by these 
cellsJ Thus, diffirential interference with T cell 
cytokine gene expression may be an important mecha-
nism whereby tacrolimus inhibits lymphocyte activa-
tion and immune suppression is maintained. 
Clues to the molecular actions of tacrolimus and 
CsA came from studies of their respective intracellu-
lar binding proteins-FKS06 binding protein (FKBP) 
and cyclophilin, each of which is a cis-trans peptidyl 
prolyl isomerase.S• lO Although binding of the drug by 
its receptor (or "immunophilin") inhibits isomerase 
activity, the immunosuppressive effects of tacrolimus 
and CsA result from the formation of complexes be-
tween the drug and its respective isomerase. I I Both 
the complexes of tacrolimus (FKS06)-FKBP and CsA-
cyclophilin bind specifically to three polypeptides-
calmodulin and the two subunits of calcineurin (a 
Ca2>-calmodulin activated, serine-threonine protein 
phosphatase). In each case, the interaction of the 
immunophilin appears to be with calcineurin. The 
drug-immunophilin complexes but neither drug nor 
either immunophilin alone, have been shown to block 
the Cal.-activated phosphatase activity of calcineurin. JO 
Calcineurin thus appears to be the molecular target 
of the drug-immunophilin complexes. 
Table 10.3.7. New immunosuppressive drugs with potential for therapy of autoimmune 
disorders 
Agent 
Deoxysperguahn 
FK506 (Tacrolimus) 
Rapamvcin 
Letlunomlde 
Mizonbine 
Mycophenolate moietil 
Brequlnar sodium 
SK&F 105685 
Structure 
semisynthetic polyamine 
carboxycyclic lactone 
carboxycyclic lactone 
isoxazole derivative 
imidazole nucleoside 
mycophenolic aCid derivative 
carboxvllc acid derivative 
azasplrane analog 
level of action 
macrophage iunctlon, cytotoxic T cells 
inhibits IL·2 production 
inhibits IL-2 action 
? B cell suppression 
inhibits DNA syntheSIS 
inhibits DNA synthesis 
inhibits DNA synthesis 
? induction oi suppressor cells 
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The second, important observation was that the 
drug-immunophilin complexes block Ca2'-dependent 
translocation of the pre-existing, cytoplasmic com-
ponent of the nuclear factor of activated T cells 
(NF-AT) to the nucleus. 12 The nuclear component 
of NF-A T is transcriptionally inactive in all cells other 
than activated T -lymphocytes, and is induced by signals 
from the TCR. Its appearance is not blocked by 
tacrolimus or CsA. It is now believed that tacrolimus 
and CsA block dephosphorylation of the cytoplasmic 
component of NF-AT which is required for its trans-
location to the nucleus. In the absence of both nuclear 
and cytoplasmic components, binding of NF-AT to 
DNA and transcriptional activation of the IL-2 gene 
is suppressed. 
EFFECTS OF TACROLIMUS 
ON IMMUNE REACTMTY 
The very potent inhibitory effects of tacrolimus 
on humoral and cell-mediated immune responses were 
first reported by Kino et al in 1987,1 using mice as 
experimental models. Subsequent reports have con-
firmed the powerful immunosuppressive properties of 
tacrolimus in rodents, dogs and primates. These in-
clude models of organ allograft rejection, ranging from 
skin grafts to multi-visceral transplants (see recent 
reviews in refs. 13-17). Tacrolimus is also effective 
in preventing and reversing graft-versus-host disease 
after experimental bone marrow transplantation. In 
each instance, tacrolimus has been shown to be about 
10-fold more potent than CsA. 
TOXICITY OF TACROLIMUS 
IN EXPERIMENTAL ANIMALS 
The toxic effects of tacrolimus in experimental 
animals (rodents, rabbits, dogs and primates) have 
been well documented. 18 Dogs are especially suscep-
tible to tacrolimus toxicity and exhibit dose-related 
vasculitis and intususseptions. Several groups have 
shown that the toxic effects of tacrolimus in nonhu-
man primates are more pronounced when the drug 
is administered i.m. compared with orally, due pre-
sumably, to the greater bioavailability achieved us-
ing the former route. T acrolimus does not exhibit 
mutagenic activity in either in vitro or in vivo tests. 
Fetotoxicity has been demonstrated in rats and ter-
atogenic effects have been observed in rabbits. 
An important issue is whether the nephrotoxic 
potential of tacrolimus and CsA (or their analogs/ 
derivatives) correlates with the drugs' PPIase inhibi-
tory activities. Recent datal? indicate that immu-
nosuppressive activity and not immunophilin bind-
ing or PPlase inhibitory activity determines the ability 
of CsA analogs to induce nephrotoxicity. It may thus 
be difficult to design new non nephrotoxic drugs that 
retain the same potent immunosuppressive activity. 
INFLUENCE OF TACROLIMUS IN 
AUTOIMMUNE DISEASE MODELS 
(See Table 10.3.2 and refs. 20-43) 
ExPERIMENTAL AUTOIMMUNE UVEITIS 
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Experimental autoimmune uveitis (EAU) is an 
organ-specific autoimmune disease of the eye that can 
be induced by immunization with retinal antigens, 
i.e., retinal soluble antigen (S-antigen) or interpho-
to receptor retinoid-binding protein (IRBP). EAU is 
believed to be T cell mediated and a good model of 
autoimmune uveitis in humans. The influence of 
tacrolimus in EAU has been studied extensively in 
the Lewis rat by Mochizuki and his colleagues. 
Tacrolimus was found to be 10-30 times more po-
tent than CsA in preventing induction of EAU when 
administered either from 0-5 days or from 7-12 days 
after S-antigen immunization. It appears that tacroli-
mus is effective in suppressing on-going immuno-
pathological processes, even after the disease has been 
initiated.20 As with CsA, the immunological unrespon-
siveness induced by a 2 week course of tacrolimus 
(days 0-14) was found to be specific to the S-anti-
gen. Whilst splenic lymphocytes from animals treated 
with either drug showed markedly depressed responses 
to S-antigen in vitro, only tacrolimus was found to 
significantly depress serum antibody levels. 21 EAU in-
duction, as well as immune responses to S-antigen 
were suppressed long after cessation of tacrolimus 
treatmen t. 22 
It has been reported that spleens of S-antigen 
immunized and tacrolimus-treated rats contain anti-
gen-specific T suppressor (Ts) cells which, when trans-
ferred to naive recipients can inhibit the induction 
of EAU. Moreover, Ts cells from the same donors 
suppress antigen-specific proliferative responses of S-
antigen primed cells without influencing responses of 
IRBP-sensitized cells.23 
Immunohistochemical studies on lymphocytes 
infiltrating the ocular lesions in EAU have revealed 
that tacrolimus reduces the absolute number of T cells, 
potentiates the recruitment of CDS- (Tc/s) cells, and 
inhibits both IL-2R expression on T cells and expres-
sion of MHC class II antigens on ocular resident cells. 24 
Further insight into the mode of action of tacrolimus 
in uveitis comes from the observation that the drug 
reduces intercellular adhesion molecule (lCAM-l) 
expression on both CD4- lymphocytes and retinal pig-
ment epithelial (RPE) cells (candidate antigen pre-
senting cells). Tacrolimus also inhibits binding of CD4' 
lymphocytes to RPE cells. 2s 
In rhesus and cynomolgus monkeys, tacrolimus 
(0.5 mg/kg/day) administered i.m. for at least 2 
weeks from 3 weeks after immunization with S-anri-
gen prevented EAU. Antibody titers against S-antigen 
were reduced, whilst S-antigen-induced lymphocyte 
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Table 10.3.2. Experimental autoimmune diseases suppressed by tacrolimus (FK506) 
Disease 
Arthritis (Type II 
collagen-induced) 
Type I diabetes 
Uveoretinitis 
Thyroiditis 
Lupus (SLE) 
Glomerulonephritis 
(Nephrotoxic 
antiserum nephritis) 
Heymann nephritis 
Allergic 
encephalomyelitis 
Autoimmune 
myocarditis 
Experimental 
allergic contact 
dermatitis 
Murine (coxsackie 
B3) myocarditis 
Species 
Rat (Lewis) 
Rat (Outbred) 
Mouse (DBA/l) 
NOD mouse 
Cyclophosphamide 
-treated NOD mouse 
BB rat 
BS rat 
Rat (Lewis) 
Rhesus & cynomolgus 
monkeys 
Rat (PVG) 
MRL-Ipr/lpr mouse 
NZB/NZW F1 mouse 
Rat (Wistar) 
Rat (Wi star) 
Rat (Wistar) 
Rat (Lewis) 
Rat (Lewis) 
Rat (Lewis) 
Farm pig 
Mice (C3H/He) 
a Suppresses Induction of disease 
b Partially effective during efferent phase of response 
c On day of immunization 
d Administered daily from 27· 120 days ot age 
e Effective only in induction phase 
f Administered from 3 weeks after immunization 
Tacrolimus Dose 
(mg/kg/day 
unless specified) 
0.32a,b 
2.se 
2.0 
2.0 mg/kgf48 hra 
0.2,1,2 
1.0a 
25 I1g Lm.d 
1.0a,e 
O.Sf 
2.08 
2 mgh 
2.5 mg/kgf48 hri 
0.3 mgi 
0.64 
0.64a 
1.0k 
1.Qi 
0.1,0.32,1 
0.04, 0.4% topical 
2.S 
g Administered for 3 weeks following Inductron of disease 
h Administered from 8 weeks of age 
i From time of immunlzatron 
j Administered 5 days per week after immunization 
k Administered from day 0-13 or 56·69 
Reference 
Inamura et al27 (1988) 
Arita et a128 (1990) 
Takagishi et al29 (1989) 
Miyagawa et aP' (1990) 
Carroll et aP2 (1991) 
Murase et apo (1990) 
Nicoletti et al33 (1991) 
Kawashima et al20 (1990) 
Fujino et al26 (1990) 
Tamura et al34 (1992) 
Yamamoto et al35 (1988) 
Takabayashi et al36 (1989) 
Hara et aP7 (1990) 
Okuba et aP8 (1990) 
Okuba et aP8 (1990) 
Matsukawa et al 39 (1992) 
Inamura et al 40 (1988) 
Hanawa et al 41 (1992) 
Meingassner & Stutz42 
(1992) 
Hiraoka et al 43 (1992) 
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proliferation in vitro was unchanged or decreased dur-
ing tacrolimus treatment.26 
ARTHRITIS 
Collagen arthritis can be induced readily in many 
rat strains by immunization with homologous or het-
erologous native type II collagen emulsified in com-
plete Freund's adjuvant (CFA). The disease is char-
acterized by the development of cellular and humoral 
responses to type II collagen and can be transferred 
by sensitized spleen and lymph node cells and by 
antibodies to type II collagen. Inamura et al27 reported 
that administration of tacrolimus to Lewis rats for 
12 days following immunization suppressed arthritis 
and inhibited both antibody and delayed-type hyper-
sensitivity (DTH) skin tests to type II collagen. Failure 
of the animals to respond to re-immunization on day 
50, but to develop experimental allergic encephalo-
myelitis in response to myelin basic protein, suggested 
the development of long-lasting, antigen-specific un-
responsiveness. 27 Studies by Arita et al2S in Sprague-
Dawley rats confirmed the efficacy of tacrolimus in 
preventing collagen-induced arthritis; a single injec-
tion of 10 mg/kg at the time of immunization sup-
pressed arthritis completely and almost abolished IgG 
antibody and OTH responses to type II collagen. They 
further showed that if withheld until day 12 or 15 
after immunization, the same single high dose of 
tacrolimus was effective in suppressing existing dis-
ease and immune (humoral) responses to type II col-
lagen. Moreover, pretreatment of rats with a single 
tacrolimus injection (10 mg/kg) (day -7 or -3) re-
duced disease severity and antibody production. 
Similar results concerning the prophylactic effect 
of tacrolimus in collagen arthritis have been obtained 
in mice using doses of drug 25 times lower than effec-
tive doses of CsA.29 As with CsA, tacrolimus was inef-
fective in treatment of established lesions in the mouse. 
INSULIN-DEPENDENT DIABETES 
Spontaneously diabetic BB rats are considered an 
excellent model for type I, insulin-dependent diabe-
tes mellitus (100M). The disease shows genetic predis-
position, abrupt onset of insulin-dependent ketosis-
prone diabetes (60-120 days of age) associated with 
lymphocytic insulitis and virtually complete destruction 
of insulin-producing pancreatic ~ cells 
(Fig. 10.3.1(a, b)). Administration of tacrolimus (2 mg/ 
kg/day) from 30 to 120 days of age prevented the 
destruction of insulin-producing cells (Fig. 10.3.1 (c, 
d» and the development of diabetes (Fig. 10.3.2) in 
20/20 BB rats during the treatment period.30 Blood 
glucose, renal and hepatic function tests remained nor-
mal, whilst histological examination confirmed the 
absence of insulitis. Glucose intolerance, which has 
been described in BB rats given CsA was not ob-
served in this study. 
775 
In nonobese diabetic (NOD) mice, IDDM de-
velops spontaneously in about 80% of female mice 
between weeks 12 and 26. The disease is thought to 
have a CD4+ T cell dependent autoimmune patho-
genesis. Administration of tacrolimus (2 mg/kg/48 hr) 
to female NOD mice from weeks 5-20 inhibited both 
the insulitis and the occurrence of diabetes (cumula-
tive incidence up to 40 weeks: 86% in control mice 
and 23% in tacrolimus-treated animals). These ef-
fects were accompanied by significant reductions in 
splenic CD4+ and CD8+ T cells compared with un-
treated controls, suggesting that the suppression of 
disease activity may be linked to inhibition of cell-
mediated autoimmune reactivity.3l 
In both the BB rat and NOD mouse studies, the 
preventive effect of tacrolimus in diabetes often 
outlasted the duration of treatment by many weeks 
or in some animals permanently. 
SPONTANEOUS AUTOIMMUNE Lupus DISEASE 
The New Zealand black/white (NZB/W) hybrid 
mouse spontaneously develops nonorgan-specific, 
autoimmune immune complex type disease that re-
sembles systemic lupus erythematosus in man. Neph-
ritis and proteinuria develop within 2-3 months of 
age, leading to chronic renal failure and 50% mor-
tality by 8-9 months. Takabayashi et aP6 reported 
that tacrolimus (2.5 mg/kg, 3 times per week from 
12 weeks of age) prolonged the lifespan of female 
NZB/W Fl mice and significantly reduced proteinuria. 
There were, however, no differences in anti-dsDNA 
antibody levels or IgG subclass distribution between 
drug-treated animals and controls. 
The MRLI Ipr mouse spontaneously develops 
glomerulonephritis, marked lymphoid hyperplasia, 
arteritis and chronic polyarthritis, with 50% morral-
ity at about 5 months. Takabayashi et aP6 reported 
similar effects of tacrolimus on survival, proteinuria 
and anti-dsDNA antibody levels in MRLI Ipr female 
mice (given 2.5 mg/kg tacrolimus 3 times per week 
from 8 weeks old) to those observed in NZB/W F 1 
hybrids. Compared with untreated MRLI Ipr controls, 
minimal glomerulonephritis with only mild prolifera-
tion of endothelial and mesangial cells was noted, 
whilst immunoglobulin and C3 deposits were restricted 
mainly to the mesangia. Using a similar tacrolimus 
treatment protocol, Yamamoto et aP5 found that in-
hibition of disease activity in MRLI Ipr mice was ac-
companied by significant reductions in serum anti-
ssONA and anti-dsONA activities. 
ExPERIMENTAL AUTOIMMUNE 
GLOMERULONEPHRITIS 
There are several ways of inducing immune-me-
diated nephritis in experimental animals. Heymann's 
nephritis is a membranous type of chronic glome-
rulonephritis with glomerular subepithelial immune 
Fig
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deposits induced by autologous antibody against re-
nal tubular brush border (TBB) antigens. It is in-
duced in rats by footpad immunization with TBB 
antigen in FCA. Another type of glomerulonephritis 
(nephrotoxic antiserum nephritis or Masugi nephritis) 
is induced by the intravenous injection of (rabbit) 
antibody to rat glomerular basement membrane 
(GBM). Okuba et aP8 have shown that tacrolimus 
(0.64 mg/kg) given for 14 days from the time of TBB 
immunization completely suppresses development of 
Heymann's nephritis. They have also found that 
tacrolimus prevents the autologous phase (i.e., pro-
duction of antibody against rabbit gamma globulin 
fixed on the GBM) of nephrotoxic antiserum nephritis. 
In both models, the rats remained tolerant to the 
immunizing antigens but not to other antigens for 
at least 14 weeks after drug withdrawal. The induc-
tion by tacrolimus of long lasting, antigen-specific 
unresponsiveness is similar to the effects of the drug 
in EAU and collagen-induced arthritis (see above). 
The underlying mechanism(s) has not been elucidated, 
but possible explanations include clonal deletion or 
the induction of anti-idiotypic antibody or antigen-
specific suppressor cells. 
Glomerulonephritis can also be induced by 
preimmunization of rats with normal rabbit IgG and 
the subsequent i.v. injection of rabbit anti-GBM 
antibody (accelerated nephrotoxic serum glomerulo-
nephritis). I n this model, tacrolimus suppresses the 
autologous response co rabbit IgG and reduces sub-
stantially the glomerular injuryY 
ExPERIMENTAL AUTOIMMUNE THYROIDITIS 
Experimental autoimmune thyroiditis can be in-
duced in female PVG/c rats by early thymectomy 
followed by a course of sublethal total body irradia-
tion (TBI). This results in progressive, lymphocytic 
infiltration of the thyroid, follicular obliteration and 
production of anti-thyroglobulin autoantibodies. Ad-
ministration of tacrolimus (2 mg/kg/day) from week 
8 after the last dose of TBI significantly decreases 
the disease severity and is associated with reversal of 
the splenic CD4+: CDS+ T cell ratio. 34 
ExPERIMENTAL ALLERGIC ENCEPHALOMYELITIS 
Experimental allergic encephalomyelitis (EAE) is 
induced in susceptible rat strains by a single injec-
tion of myelin basic protein (MBP) in FCA. An acute 
paralytic disease develops within 10-14 days after 
immunization with features similar to human acute 
inflammatory central nervous system disease. Tacroli-
mus (1 mg/kg 5 days per week for 2 weeks from the 
time of immunization) prevented development of EAE 
for at least 50 days and completely suppressed both 
antibody production and cell-mediated immunity to 
MBP. The effectiveness of the drug, however, was 
considerably reduced when treatment was delayed until 
7 days after immunization;IO It has been observed that 
the adoptive transfer of EAE can be suppressed by 
in vitro treatment of spleen cells with 1 nM tacrolimus, 
IOO-fold lower than (he effective concentration of 
CSA.44 
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COMBINED T AND B CELL DIRECTED 
THERAPY OF SPONTANEOUS 
AUTOIMMUNE DISEASE USING 
TACROLIMUS AND LOW DOSE 
CYCLOPHOSPHAMIDE 
Autoimmune diseases in which autoantibodies and 
immune complexes appear to playa dominant role, 
such as SLE, various vasculitides and glomerulo-
nephritis have not responded as favorably to CsA as 
those disorders that are thought to be predominantly 
T cell driven. The current management of the former 
disorders includes treatment with varying doses of 
corticosteroids and for certain organ system involve-
ment, use of cyclophosphamide (Cy):15 Responses are 
frequently only partial however, and often associated 
with severe side effects, including life-threatening 
infections. 
The search for improved strategies of immuno-
suppressive therapy includes the evaluation of com-
binations of drugs with complementary actions. In 
principle, two or more agents can be used together 
at reduced dosage to achieve additive or synergistic 
therapeutic effects while minimizing toxicity. Recently, 
it has been shown that combination of either of the 
T cell suppressants, CsA46 or tacrolimus47 with the 
alkylating agent CY can effectively control the strong 
antibody and cell-mediated responses evoked by con-
cordant xenografts in experimental animals. Moreover, 
this approach has been found to prolong graft sur-
vival much longer than drug mono therapy. There-
fore, it is possible that the combination of CsA or 
tacrolimus with CY may prove valuable in the treat-
ment of autoimmune disorders in which both T cells 
and antibody-producing B cells are thought to play 
important pathogenic roles. 
Mice homozygous for the lpr gene that encodes 
a defective allele of the apoptosis regulatory gene Fas48 
spontaneously develop an aggressive T cell dependent 
autoimmune disease that resembles human SLE.49-51 
MRL-lpr//pr mice also develop high levels of autoan-
tibodies, associated with glomerulonephritis and 
vasculitis, interstitial pneumonitis, arthritis (in some, 
but not all colonies) and premature death. It has been 
shown (see above) that high doses of tacrolimus can 
inhibit disease progression and prolong survival. The 
incidence of proteinuria and anti-DNA autoantibodies 
may however, remain high. 35•36 Since a combination 
of tacrolimus and CY has been shown to be effective 
in controlling both T cell and antibody-mediated 
immune responses in vivo, we have examined the effect 
of this drug combination on the development of au-
toimmune disease in MRL-lpr mice. 
Groups of female MRL-/pr mice received either 
saline or tacrolimus (2 mg/kg i.p) thrice weekly, CY 
(20 mg/kg) once monthly, or both drugs from 8 weeks 
of age. Median survival for untreated and CY-treated 
mice was 26 weeks and for tacrolimus and tacrolimus 
+ CY-treated groups was> 44 weeks. 52 Severity of 
skin lesions and lymph node hyperplasia was mark-
edly reduced by the drug combination, whereas ei-
ther drug alone was less effective (Table 10.3.3). 
Tacrolimus or CY alone delayed the onset of pro-
teinuria, but by 24 weeks all of these animals were 
positive. In contrast, drug combination reduced the 
prevalence and severity of proteinuria throughout the 
44 weeks of study (Fig. 10.3.3). Sequential monitor-
ing of peripheral blood lymphocytes revealed that 
combination therapy but not mono therapy markedly 
reduced the proportion of atypical CD3+ B220+ and 
CD3+CD4-CD8- T cells. Serum levels of anti-dsDNA 
antibodies were reduced in all treatment groups. 
Analysis of tissue from saline-treated mice that died 
spontaneously showed as anticipated, evidence of ex-
tensive diffuse interstitial disease, diffuse proliferative 
glomerulonephritis with crescents, and vasculitis 
(Fig. 10.3.4(a)). Similarly, the CY-treated mice showed 
Table 10.3.3. Influence of tacrolimus (FK506) and tacrolimus + cyclophosphamide (CY) on 
the clinical disease index (lymphoid hyperplasia, exudative dermatitis and ear necrosis) in 
female MRL-Ipr mice 
Treatment Saline Tacrolimus CY Tacrolimus + CY 
Age (weeks) 
8 0(10) 0(10) 0(6) 0(10) 
12 0(10) 0(10) 0(6) 0(10) 
16 1.4 ± 0.9(9) 1.2 ± 0.4(10) 1.2 ± 0.4(4) 1.0 ± o.sa(lO) 
20 1.8 ± 0.6(7) 0.9 ± 0.4(10) 1.8 ± 0.9(4) 0.6 ± 0.6b( 10) 
24 2.5 ±0.6(S) 1.9± 0.8(10) 1.8 ± 0.9(4) 0.9 ± 0.9b(lO) 
33 3.0(1) 2.8 ± 1.2(9) 3.5(1) 1.3 ± 1.2( 10) 
44 No survivors 2.6 ± 1.3(7) 2.5(1 ) 1.3 ± 1.3(7) 
0-, no physical signs; clinical involvement scored 14 (most severe). Total score tor each group was divided by the 
total number oi mice alive (in parentheses) when determinations were made. 
d, p < 0.05; b, p < 0.01 compared with saline-treated control. 
Reproduced with permission irom Woo J et al. elin Exp Immunol 1995; 100: 118.125.52 
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Proteinuria in MRL-lpr/lpr Mice 
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Fig, 10.3.3, Effects of tacrolimus (FK506), CYor 
tacrolimus + CY therapy (started at 8 weeks of 
age) on the extent of proteinuria in individual 
female MRL-Ipr mice from 16-44 weeks of age. 
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severe interstitial and glomerular disease with vasculitis 
(Fig. lO.3.4(b». In contrast. the kidneys of mice 
treated with tacrolimus or tacrolimus + Cy (Figs. 10.3.4 
(c.d)). sacrificed at 44 weeks showed only moderate 
focal interstitial and glomerular changes. There was 
no significant difference in the severity of renal dis-
ease between the tacrolimus and tacrolimus + Cy 
groups. These data demonstrate the improved effi-
cacy of combined T and B cell directed immuno-
suppression in murine lupus. associated with marked 
inhibition of atypical T cells within the affected lym-
phoid tissue. Since Cy is used currently in the treat-
ment of SLE, the combined use of these powerful 
immunosuppressants for the more effective control 
of this debilitating disease is worthy of further evalu-
ation. 
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